VINDESINE, CARMUSTINE, DOXORUBICIN, AND PREDNISONE (EBAP) IN RECURRENT LYMPHOMAS - A SOUTHWEST ONCOLOGY GROUP-STUDY

  • 1 January 1984
    • journal article
    • research article
    • Vol. 68  (7-8) , 963-967
Abstract
Patients (78) with Hodgkin''s disease and non-Hodgkin''s lymphoma who had failed prior chemotherapy or radiation therapy were treated with a combination of vindesine, carmustine, doxorubicin and prednisone (EBAP). Outpatient therapy was administered at 21-day intervals. Complete and partial responses were seen in 32 patients (41%). The response rate was higher for Hodgkin''s disease (59%) than for non-Hodgkin''s lymphoma (31%). The median duration of response was 31 wk in both groups, with a median survival of all patients of 35 wk (responders, 122 wk; nonresponders, 16 wk). Myelotoxicity was greater using EBAP than in the earlier reported program with vincristine, carmustine, doxorubicin and prednisone, and in the absence of higher response rates does not support the use of vindesine over vincristine in combination programs using nitrosoureas, anthracyclines and prednisone.